Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Still a Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $40.99, but opened at $43.94. Zealand Pharma A/S shares last traded at $43.94, with a volume of 368 shares.

Analyst Ratings Changes

A number of research firms recently issued reports on ZLDPF. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. BTIG Research raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Finally, BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Three research analysts have rated the stock with a Strong Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Zealand Pharma A/S currently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Trading Up 8.4%

The stock has a 50 day moving average of $57.32 and a 200-day moving average of $68.49. The company has a market capitalization of $3.16 billion, a P/E ratio of 3.25 and a beta of 0.75. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 48.10%. The firm had revenue of $10.79 million for the quarter, compared to the consensus estimate of $19.69 million. On average, research analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.